Huang, Tony P.
Heins, Zachary J. http://orcid.org/0000-0002-4058-0017
Miller, Shannon M.
Wong, Brandon G.
Balivada, Pallavi A. http://orcid.org/0000-0003-2153-8515
Wang, Tina http://orcid.org/0000-0001-7259-7449
Khalil, Ahmad S. http://orcid.org/0000-0002-8214-0546
Liu, David R. http://orcid.org/0000-0002-9943-7557
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB027793, R01EB031172)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01AI142756)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
Howard Hughes Medical Institute (Liu investigatorship)
Article History
Received: 4 February 2022
Accepted: 30 June 2022
First Online: 8 September 2022
Competing interests
: The authors declare the following competing financial interests: T.P.H., Z.J.H., A.S.K. and D.R.L. have filed patent applications on this work. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine and Resonance Medicine, companies that use genome editing, epigenome engineering or PACE, and owns equity in these companies. A.S.K. is a scientific advisor for and holds equity in Chroma Medicine, and is a cofounder of Fynch Biosciences, which manufactures eVOLVER hardware, and K2 Biotechnologies, which focuses on the use of continuous evolution technologies applied to antibody engineering.